2079

Samsung Biologics Co Ltd

207940.KO samsungbiologics.com + Research + Basket
ISIN KR7207940008
Employees 5,326
Phone 82 3 2455 3114
Fiscal year end December
Address 300, Songdo bio-daero, Incheon, South Korea
1,516,000.00
-4,000.00 (-0.26%)
KRW · KO
52-week range
1,150,000.00
1,973,601.63
Trading at 44% of the 52-week range
Market Cap
70.76T
P/E Ratio
37.63
Forward P/E
36.76
Book Value
179,619.85
Div. Yield
N/A
% Institutions
16.32%
% Insiders
74.36%

1 Year

-14.7%

3 Year

+41.7%

10 Year

+627.8%
Description

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Actions

Add an action for 207940.KO, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. John Chongbo Rim CEO, President & Chairman of Board 1961
Dr. Kun Lo Ph.D. Executive VP, Head of EPCV Center & Director 1963
Mr. Seung ho Ryu EVP, CFO, Head of Business Support Center & Director 1968
Mr. Kevin Sharp EVP, Head of Sales & Operations Department NA
Mr. Kyuho Lee Executive VP, Head of People Center, & Chief Human Resource Officer NA
Mr. James J. Choi Executive VP, Head of CDO Development Center & Head of Sales Center 1967
Mr. Heekyun Lim VP & Head of Business Consulting Team 1975
Sojeong Lee VP & Head of Regulatory Affairs NA
Ms. Heejeong Kim VP & Head of Drug Substance Department NA
Mr. Sangmyung Lee VP & Head of CDO Development NA

Financial Highlights

▼
Market Cap: $70,761.24B
EBITDA: $2,827.65B
P/E Ratio: $37.63
PEG Ratio: $1.79
Book Value: $179.62K
Earnings/Share: $39.72K
Profit Margin: 38.75%
Operating Margin: 44.40%
ROA (TTM): 9.57%
ROE (TTM): 18.53%
Revenue (TTM): $5,121.22B
Revenue/Share (TTM): $117.57K
Earnings Growth (YOY): 32.90%
Revenue Growth (YOY): 30.20%

Valuation Metrics

Enterprise Value: $68,625.74B
Trailing P/E: 37.63
Forward P/E: 36.76

Shares Statistics

Shares Outstanding: 46.55M
Shares Float: 11.81M
% Insiders: 74.36%
% Institutions: 16.32%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$4,556.97B
Cost of Goods Sold
adjust
$-2,040.33B
Gross Profit
subtotal
$2,516.64B
SG&A
adjust
$-169.63B
R&D
adjust
$-37.18B
Other Operating Expense
adjust
$-2,280.94B
Operating Income
subtotal
$2,069.22B
Other / Non-Operating Items
adjust
$-284.87B
Net Income
subtotal
$1,784.35B

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about 207940.KO!